A biomaterial platform for T cell-specific gene delivery.

Area of Science:

• Biotechnology
• Immunotherapy
• Cellular Engineering

Background:

• CAR T cell therapy requires complex, multi-step T cell engineering.
• Current manufacturing processes are time-consuming, taking up to 4 weeks.
• This complexity limits patient access to advanced T cell therapies.

Purpose of the Study:

• To develop a simplified, single-step method for T cell activation and transduction.
• To streamline the manufacturing process for CAR T cell therapy.
• To enhance the efficiency and accessibility of T cell engineering.

Main Methods:

• Utilized T cell-specific lentiviral vectors (STAT virus) displaying anti-CD3 antibody and CD80.
• Employed biocompatible macroporous scaffolds (Drydux) for enhanced T cell-viral vector interaction.
• Combined STAT virus and Drydux scaffold for simultaneous T cell activation and transduction of PBMCs.

Main Results:

• Achieved selective T cell activation and transduction in a single step using the STAT virus and Drydux platform.
• Demonstrated the generation of tumor-specific functional CAR T cells from unstimulated PBMCs.
• Showcased a simplified and efficient T cell engineering process.

Conclusions:

• The combination of STAT lentivirus and Drydux scaffolds offers a potent, simple, and safe approach for T cell engineering.
• This novel platform significantly reduces manufacturing time and complexity for CAR T cell therapies.
• Holds promise for improving in vitro and in vivo T cell manipulation and expanding patient access.